Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
IMMX is expected to report earnings to rise 40.00% to -20 cents per share on September 03
Q2'25
Est.
$-0.21
Q1'25
Beat
by $0.08
Q4'24
Est.
$-0.25
Q3'24
Missed
by $0.08
Q2'24
Est.
$-0.15
The last earnings report on May 28 showed earnings per share of -15 cents, beating the estimate of -23 cents. With 170.81K shares outstanding, the current market capitalization sits at 60.08M.